{"url_path":"/sec/fth/10-k/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-K/A","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-252637-index.html","accession_number":"0001193125-26-252637","cik":"0001829802","ticker":"FTH","issuer_name":"Faeth Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-252637-index.html","primary_entity_key":"0001829802","primary_entity_name":"Sensei Biotherapeutics, Inc."},"word_count":722,"has_tables":true,"body_markdown":"10-K/A\n\n##### Table of Contents\n\ntrueFYYes0001829802YesMDNoNo 0001829802 2025-01-01 2025-12-31 0001829802 2026-03-23 0001829802 2025-06-30 xbrli:shares iso4217:USD\n\n \n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\n \n\n \n\nFORM\n10-K/A\n\n(Amendment No. 1)\n\n \n\n \n\n(Mark One)\n\n☒\n\nANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the fiscal year ended December 31, 2025\n\nOR\n\n \n\n☐\n\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFOR THE TRANSITION PERIOD FROM      TO     \n\nCommission File Number:\n001-39980\n\n \n\n \n\nSensei Biotherapeutics, Inc.\n\n(Exact name of Registrant as specified in its Charter)\n\n \n\n \n\n \n\nDelaware\n\n \n\n83-1863385\n\n(State or other jurisdiction of\n\nincorporation or organization)\n\n \n\n(I.R.S. Employer\n\nIdentification No.)\n\n1405 Research Boulevard, Suite 125\n\nRockville,\nMD\n\n \n\n20850\n\n(Address of principal executive offices)\n\n \n\n(Zip Code)\n\nRegistrant’s telephone number, including area code: (240)\n243-8000\n\n \n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n\n \n\nTrading Symbol(s)\n\n \n\nName of each exchange on which registered\n\nCommon Stock, $0.0001 par value per share\n \nSNSE\n \nThe Nasdaq Stock Market LLC\n\nSecurities registered pursuant to Section 12(g) of the Act: None\n \n\nIndicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☐ \nNO\n ☒\n\nIndicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES ☐ \nNO\n ☒\n\nIndicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. \nYES\n ☒ NO ☐\n\nIndicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation\nS-T\n(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). \nYES\n ☒ NO ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a\nnon-accelerated\nfiler, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule\n12b-2\nof the Exchange Act.\n\n \n\nLarge accelerated filer\n \n☐\n  \nAccelerated filer\n \n☐\n\nNon-accelerated\nfiler\n \n☒\n  \nSmaller reporting company\n \n☒\n\n \n\n  \nEmerging growth company\n \n☒\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐\n\nIf securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐\n\nIndicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to\n§240.10D-1(b). ☐\n\nIndicate by check mark whether the Registrant is a shell company (as defined in Rule\n12b-2\nof the Exchange Act). YES ☐ NO ☒\n\nAs of June 30, 2025 (the last business day of the Registrant’s second fiscal quarter), the Registrant’s aggregate market value of its voting common equity held by\nnon-affiliates\nwas approximately $7.1 million based on the closing sale price of $8.58 per share as reported on the Nasdaq Capital Market on that date. The number of shares of Registrant’s Common Stock outstanding as of March 23, 2026 was 1,340,281.\n\nDOCUMENTS INCORPORATED BY REFERENCE\n\nPortions of the Registrant’s definitive proxy statement, to be filed pursuant to Regulation 14A under the Securities Exchange Act of 1934, for its 2026 Annual Meeting of Stockholders are incorporated by reference in Part III of this Form\n10-K.\n\n \n\n \n\n \n\n##### Table of Contents\n\nTable of Contents\n\n \n\n \n  \n \n  \nPage\n \n\nPART I"}